Vancomycin dosing in neonates: enhancing outcomes using population pharmacokinetics and simulation
Incorporating developmental factors like PMA and SCr into vancomycin dosing strategies achieved robust and clinically relevant outcomes. The optimized regimens achieved an 80% PTA for the AUC<sub>24</sub>/MIC target for preterm and term neonates. These findings offer a scalable framework for improving neonatal vancomycin pharmacotherapy across diverse populations and clinical settings.
Authors
- Shaun S. Kumar
- David Reith (ORCID: https://orcid.org/0000-0002-2447-365X)
- Angela K. Birnbaum (ORCID: https://orcid.org/0000-0002-3969-4906)
- David Haslam (ORCID: https://orcid.org/0000-0002-2143-5869)
- Jiraganya Bhongsatiern (ORCID: https://orcid.org/0000-0001-5384-9647)
- Catherine M.T. Sherwin (ORCID: https://orcid.org/0000-0002-0844-3207)
- Pankaj B. Desai (ORCID: https://orcid.org/0000-0002-3001-1603)
- Sílvia M. Illamola (ORCID: https://orcid.org/0000-0003-3245-1626)
- Karel Allegaert (ORCID: https://orcid.org/0000-0001-9921-5105)
- Joshua Courter
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- University of Minnesota (US)
- PAREXEL International (United Kingdom) (GB)
- The University of Western Australia (AU)
- Regeneron (United States) (US)
- Wright State University (US)
- University of Utah (US)
- Erasmus MC (NL)
- Natus (United States) (US)
- University of Cincinnati (US)
- University of Otago (NZ)
- Erasmus University Rotterdam (NL)
- KU Leuven (BE)
Publication Details
- Journal
- Frontiers in Antibiotics
- Published
- 2025-05-08
- DOI
- https://doi.org/10.3389/frabi.2025.1568931
- Citations
- 1
- Primary Topic
- Antimicrobial Resistance in Staphylococcus
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Intermountain Healthcare
- University of Minnesota
- School of Medicine
- College of Pharmacy, University of Minnesota